Maternal and fetal outcome Our Study Retrospective Di Cianni et al.
Retrospective
[14]
Fang et al.
Retrospective
[15]
Negratoet al.
Observational prospective
[12]
Ergman et al.
Retrospective
[16]
Number of patients on glargine 92 43 52 55 65
Intrauterine deaths 1.1 % 6 (abortions) 1 (fetal death) 0 (fetal death) X
Preeclampsia 7.6 % 2.3% 1.9 % 1.8% 25%
Cesarean section 45% 79% 53  % X 65 %
Maternal hypoglycemia 31% 9.3% 1.9 % 1.8% X
Mean gestational (±SD; weeks) 36.2 ± 4.38 37.2  ±  1.5 37.8 ± 0.9 37.2± 1.4 37.3 ± 2.8
Five minute Apgar score <7 4.7%   X 2% 0 X
Macrosomia (>4000 grams) 12.3 % 21 % X 18 % X
Shoulder Dystocia 2.1 % X X X 0%
Fetal Hypoglycemia 6.5 % 14.6% 2% 5.4% 29%
X indicates that no data is reported in those studies
Data is presented as mean plus standard deviation.
Ref [12,14-16]
Table 3: Maternal and fetal outcomes in patients using insulin glargine during pregnancy.